Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

41,479 stories, page 446 of 692

Advanced search

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

'Not scientifically supportable:' Inside FDA’s refusal to face US generic drug crisis

WSBTOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Krystal Biotech sets Aug. 3 webcast before U.S. markets open

Stock TitanOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

'Not scientifically supportable:' Inside FDA’s refusal to face US generic drug crisis

National News DeskOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?

The Motley FoolOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical Services Inc 2Q 2026: Revenue $872.3M, EPS $2.15— 10-Q Summary

TradingViewOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

[10-Q] WEST PHARMACEUTICAL SERVICES INC Quarterly Earnings Report

Stock TitanOriginal source

🇺🇸Jul 24Industryir.codexis.comTier 1 · Company source

Codexis Announces Proposed Public Offering of Common Stock

CodexisOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Eli Lilly Reports Positive Results from Two Phase III Trials | PharmExec

Pharmaceutical ExecutiveOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

The Manila TimesOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Twin Phase 3 studies recruiting adults with lupus skin problems in US, Canada

Lupus News TodayOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Business WireOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

West Pharma says sterile packaging upgrades fuel demand for high-value plastics

Plastics NewsOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?

The Globe and MailOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026?

The Globe and MailOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Retatrutide Helped Adults With Diabetes or Heart Disease Lose Up to 20 Percent of Their Weight, Study Finds

Yahoo HealthOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Peptides are surging in popularity. What are they, and do they work? Why doctors are urging caution.

UCHealthOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Trump Plans to Impose 100% Tariffs on Generic Drugs Starting in 2028. What Would That Do to Prices?

Time MagazineOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Pennsylvania Biotech Center pauses expansion amid funding crunch

The Business JournalsOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Playing The Biotech Breakout With Insiders

Seeking AlphaOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

IntrepidX Appoints Taylor Judd as Director of Business Development to Expand Pharmaceutical Litigation Practice

citybizOriginal source

🇺🇸Jul 24Researchrarediseases.orgTier 2 · Direct publisher

How I Learned to Embrace My White Cane: Life with Bardet-Biedl Syndrome

NORD Rare DiseasesOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical (WST) Receives Strong Outlook Amidst Quarterly Performance

GuruFocusOriginal source

🌍Jul 24discoverynews.google.comTier 2 · Trade media

UPDATE: Peptides favored on 1st day of closely watched FDA compounding adcomm

Fierce PharmaOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical Services Inc (WST) Q2 2026 Earnings Call Highlights: Strong Organic Growth ...

Yahoo FinanceOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Food safety alerts, FDA wellness reviews and planning for retirement health costs

KGWOriginal source

🌍Jul 24discoverynews.google.comTier 2 · Trade media

Neuphoria Therapeutics

Fierce BiotechOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Antibacterial Drug Partnership Accelerates PolyPid Commercial Path

Streetwise ReportsOriginal source

🇺🇸Jul 24Research5amventures.comTier 2 · Direct publisher

Kinaset Therapeutics Announces First Patient Dosed in Phase 2b PANAIRAMA Trial of frevecitinib (KN-002) in Patients with Severe Asthma

5AM VenturesOriginal source

🇺🇸Jul 24Research5amventures.comTier 2 · Direct publisher

Nouscom Selected for Oral Presentation on NOUS-209 Re-Treatment and Long-Term Follow-up in Lynch Syndrome Carriers at ESMO Congress 2026

5AM VenturesOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

FDA advisory committee votes to add popular peptide BPC-157 to drug compounding list

ABC News - Breaking News, Latest News and VideosOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Sartorius Stedim Biotech SA (SDMHF) Q2 2026 Earnings Call Highli

GuruFocusOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

VERAXA Biotech (VRXA) Advances BiTAC®-TCE Development With Positive Regulatory Feedback From Germany

NewMediaWireOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical Services Inc (WST) Q2 2026 Earnings Call Hig

GuruFocusOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

FDA Panel Narrowly Backs Unapproved Peptide Drug

NewsmaxOriginal source

🇺🇸Jul 24Industrybiomarin.comTier 1 · Company source

Megan Bull’s Childhood Empathy Fuels a Career of Impact

BioMarin PharmaceuticalOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

WST Stock Jumps on Q2 Earnings & Sales Beat, EPS View Up on HVP Growth

TradingViewOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Is Patient Affordability Better or Worse in 2026?

Pharmaceutical CommerceOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

A Peptide Showdown: F.D.A. Scientists May Clash With R.F.K.’s Agenda

The New York TimesOriginal source

🌍Jul 24discoverynews.google.comTier 2 · Trade media

Bora Pharmaceuticals and Onconic Therapeutics Sign Manufacturing Agreement to Support U.S. Clinical Development of JAQBO Tablets

BioSpaceOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Canton Strategic sells biotech unit to focus on blockchain

Investing.comOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

FDA Meeting to Review Safety and Efficacy of Popular Peptides Amid Controversy

SSBCrackOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

FDA panel narrowly backs unapproved peptide drug touted by Joe Rogan and other influencers

Orlando SentinelOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Why Teva Pharmaceutical Stock Is a Buy Despite Trump Tariff Threat

Barron'sOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Cell Therapy TG-C Misses Primary Endpoints in Phase 3 Knee Osteoarthritis Trial

CGTLive®Original source

🇨🇦Jul 24Researchwomenscollegehospital.caTier 2 · Direct publisher

WCH researcher awarded Canadian Cancer Society Emerging Scholar Research Grant

Women's College HospitalOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Cash flow from operating activities of Teh Seng Pharmaceutical Mfg Co Ltd – TPEX:7860

TradingViewOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Free cash flow of Teh Seng Pharmaceutical Mfg Co Ltd – TPEX:7860

TradingViewOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Lonza, with big Vacaville biotech campus, reports strong first half

The Press DemocratOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Landscape Analysis of the Integration of AI into Pharmaceutical Innovation | Part 1

JD SupraOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany

TradingViewOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Ge

BenzingaOriginal source

🇪🇺Jul 24Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Centre for New Methods in Computational Diagnostics and Personalised Therapy

CORDISOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical beats Q2 earnings estimates, raises outlook on strong injectable drug demand

PluangOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer

citybizOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

FDA advisers back first four of seven unapproved peptides under review for looser rules

ReutersOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

West Pharmaceutical Services (WST) Reports Strong Q2 2026 Earnin

GuruFocusOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

EU Pharmaceutical Law Forum: Key Insights 2026

BioXconomyOriginal source

🇺🇸Jul 24Industryimmunovant.comTier 1 · Company source

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that...

ImmunovantOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

Biotech is back, baby! A wave of life science deals is pumping cash into the sector.

The Boston GlobeOriginal source

🌍Jul 24discoverynews.google.comTier 3 · Aggregated media

OKYO Pharma Director's Holding Reaches 35,201 Shares

Stock TitanOriginal source